Metagenomi Therapeutics's three largest insider shareholders as of September 29, 2026 are Healthcare Llc Bayer (TenPercentOwner, 4.05Mn shares), Brian C. Thomas (Chief Executive Officer, 2.51Mn shares), Sebastian Bernales (Director, 1.90Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Healthcare Llc Bayer | TenPercentOwner | 4,050,997 | 0 | 4,050,997 | 33.5% | 15 Feb, 2024 |
| 2 | Sebastian Bernales | Director | 769,845 | 1,896,445 | 2,666,290 | 22.1% | 14 Feb, 2024 |
| 3 | Brian C. Thomas | Chief Executive Officer | 2,510,960 | 0 | 2,510,960 | 20.8% | 08 Dec, 2025 |
| 4 | Holdings A/S Novo | TenPercentOwner | 1,739,175 | 0 | 1,739,175 | 14.4% | 15 Feb, 2024 |
| 5 | Jian Irish | Chief Executive Officer | 375,393 | 0 | 375,393 | 3.1% | 10 Sep, 2026 |
| 6 | Pamela Wapnick | Chief Financial Officer | 206,580 | 0 | 206,580 | 1.7% | 10 Sep, 2026 |
| 7 | Matthew Wein | Officer | 126,133 | 0 | 126,133 | 1.0% | 10 Sep, 2026 |
| 8 | Simon Harnest | Officer | 122,664 | 0 | 122,664 | 1.0% | 03 Apr, 2024 |
| 9 | Sarah B. Noonberg | Chief Medical Officer | 109,135 | 0 | 109,135 | 0.9% | 09 Jun, 2025 |
| 10 | Simren Delaney | Officer | 93,892 | 0 | 93,892 | 0.8% | 03 Apr, 2024 |
| 11 | Luis Borges | Chief Scientific Officer | 69,316 | 0 | 69,316 | 0.6% | 03 Apr, 2024 |
| 12 | Laurence Reid | Director | 20,000 | 0 | 20,000 | 0.2% | 11 Sep, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 09 Sep, 2026 | Laurence Reid | Director | Acquired P | 19,883 | $1.17 | $23.26K | 19,883 | Direct |
| 09 Sep, 2026 | Laurence Reid | Director | Acquired P | 117 | $1.18 | $138 | 20,000 | Direct |
| 08 Sep, 2026 | Matthew Wein | Officer | Disposed S | 358 | $1.16 | $415 | 126,133 | Direct |
| 08 Sep, 2026 | Jian Irish | Director, Officer | Disposed S | 2,140 | $1.16 | $2.48K | 375,393 | Direct |
| 08 Sep, 2026 | Pamela Wapnick | Chief Financial Officer | Disposed S | 1,911 | $1.16 | $2.21K | 206,580 | Direct |
| 09 Jun, 2026 | Laurence Reid | Director | Acquired A | 17,400 | $0.00 | $0 | 17,400 | Direct |
| 09 Jun, 2026 | Juergen Eckhardt | Director | Acquired A | 21,000 | $0.00 | $0 | 21,000 | Direct |
| 09 Jun, 2026 | Willard H Dere | Director | Acquired A | 21,000 | $0.00 | $0 | 21,000 | Direct |
| 09 Jun, 2026 | Eric Bjerkholt | Director | Acquired A | 21,000 | $0.00 | $0 | 21,000 | Direct |
| 05 Jun, 2026 | Jian Irish | Director, Officer | Disposed S | 3,737 | $1.30 | $4.85K | 377,533 | Direct |
| 05 Jun, 2026 | Matthew Wein | Officer | Disposed S | 558 | $1.30 | $725 | 126,491 | Direct |
| 05 Jun, 2026 | Pamela Wapnick | Chief Financial Officer | Disposed S | 2,884 | $1.30 | $3.75K | 208,491 | Direct |
| 01 Apr, 2026 | Matthew Wein | Officer | Acquired A | 11,000 | $0.00 | $0 | 125,549 | Direct |
| 01 Apr, 2026 | Pamela Wapnick | Chief Financial Officer | Acquired A | 24,000 | $0.00 | $0 | 211,375 | Direct |
| 01 Apr, 2026 | Jian Irish | Director, Officer | Acquired A | 46,000 | $0.00 | $0 | 379,770 | Direct |
| 01 Apr, 2026 | Matthew Wein | Officer | Acquired A | 68,000 | $0.00 | $0 | 68,000 | Direct |
| 01 Apr, 2026 | Pamela Wapnick | Chief Financial Officer | Acquired A | 144,000 | $0.00 | $0 | 144,000 | Direct |
| 01 Apr, 2026 | Jian Irish | Director, Officer | Acquired A | 276,000 | $0.00 | $0 | 276,000 | Direct |
| 05 Mar, 2026 | Pamela Wapnick | Chief Financial Officer | Disposed S | 1,581 | $1.60 | $2.53K | 187,375 | Direct |
| 05 Mar, 2026 | Matthew Wein | Officer | Disposed S | 482 | $1.60 | $771 | 114,549 | Direct |